Nuvectis Pharma (NVCT) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed Verastem (VSTM) over the past year, gaining 232.1% versus a loss of 8.2%. Verastem is the larger company by market cap ($723.6 million vs $661.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVCT | VSTM |
|---|---|---|
| Share price | $20.27 | $7.99 |
| Market cap | $661.70M | $723.60M |
| 1-day change | -0.10% | -3.33% |
| YTD return | +168.74% | +7.06% |
| 1-year return | +232.08% | -8.17% |
| 5-year return | — | -75.05% |
| EPS (TTM) | $-1.31 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.28 | $10.82 |
| 52-week low | $5.55 | $3.43 |
| Distance from 52-week high | -30.76% | -26.16% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +74.64% | +83.60% |
| Average volume | 217.91K | 2.29M |
| Shares outstanding | 32.64M | 90.56M |
| Employees | 16 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed VSTM by 240.2 percentage points over the past year.
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
NVCT vs VSTM FAQ
Which is bigger, Nuvectis Pharma or Verastem?
Verastem (VSTM) is larger, with a market capitalization of $723.60M compared with $661.70M for Nuvectis Pharma (NVCT).
Which stock has performed better over the past year, NVCT or VSTM?
NVCT returned +232.08% over the past 12 months, compared with -8.17% for VSTM (price return, excluding dividends). Past performance does not predict future results.
Are Nuvectis Pharma and Verastem in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.